

German University Hospital selects C-RAD's cutting-edge SGRT solution

C-RAD announced today an order for the Catalyst+ HD[™] and Sentinel 4DCT[™] from the University Hospital Regensburg. The order includes multiple systems and a multiyear service agreement.

The University Hospital Regensburg has become one of the most modern as well as one of the most efficient hospitals in Germany since its establishment in 1992. Top quality patient care always has been and always will be the main focus.[1]

The systems will be delivered with the complete software suite including modules for Respiratory Gating, Patient Setup & Positioning and Motion Monitoring as well as a dedicated software that supports stereotactic treatments. The C-RAD SGRT system (Surface Guided Radiation Therapy) provides the customer with a tool for accurate patient setup prior to the treatment and continuous monitoring of the patient during a treatment fraction. The technology provides accuracy and safety for the patient to support high precision treatment techniques as well as efficiency in a complex treatment workflow.

"We are excited to work with the team to implement surface tracking at this progressive university hospital." says Tim Thurn, CEO and President of C-RAD AB, "The cooperation has the potential for a closer partnership to elevate the standard of care in advanced radiation therapy."

The total order has a value of approx. 10 MSEK for C-RAD. Delivery and installation are expected to commence before the end of the year.

[1] https://www.ukr.de/e/about-us/index.php

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

Press Release 18 March 2022 10:00:00 CET



About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-03-18 10:00 CET.

Attachments

German University Hospital selects C-RAD's cutting-edge SGRT solution